The principal objective of the Geisinger Clinical Oncology Program is to enroll maximal numbers of patients into NCI-approved cancer prevention, cancer control and cancer treatment clinical trials, thus bringing research-quality care to a large rural population of Pennsylvania. The Geisinger health care system serves more than 2.1 million Pennsylvanians across 31 primarily rural counties, from the state's northeastern corner to its midpoint. It is based on a 500-physician multispecialty group practice in 45 sites, anchored by a 577-bed tertiary care medical center in Danville--Geisinger Medical Center. This proposal will incorporate the multispecialty clinical and research facilities that are already in place with a new affiliate at the Geisinger Wyoming Valley Medical Center, a 230 bed secondary care referral hospital, with a 100 physician Geisinger group practice and a newly constructed cancer center on site. In addition, the Oncology Program will take advantage of the largest HMO in our region--the Geisinger Health Plan--with its 140,000 members, to enroll large numbers of normal subjects on cancer prevention trials. Geisinger continues to offer special advantages for continuation of the CCOP program: 1. Large cancer patient population for treatment/control studies. 2. Large population served generally, with research access to primary care practices and """"""""normal"""""""" populations (1.198,225 clinic visits in 1992). 3. Stable, experience CCOP staff with a 10 year record of successful accrual to NCI treatment/control trials, successful relations with cooperative groups and consistently superb data quality. 4. Excellent patient record system, with unit charts, system-wide computerized lab, Computerized cancer registry which includes Geisinger (Danville) and GWV hospitals. 5. Fulltime, salaried multispecialty physician staff, able to provide all needed cancer treatment services under one roof both at Danville and GWV. 6. Successful competition to be a study center for the important Prostate Cancer Prevention Trial (PCPT), which starts October, 1993. 7. Strong institutional commitment to clinical trial research in cancer, with willingness to co-sponsor the costs of this research along with the NCI, despite increasingly tight financial times for all health care institutions. Geisinger openly recognizes this as a primary mission, not just a marketing tool. The proposal retains NCCTG as our primary research base; includes ECOG and CCG bases also.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035448-14
Application #
2429669
Study Section
Special Emphasis Panel (SRC (74))
Project Start
1983-09-15
Project End
1998-05-31
Budget Start
1997-09-22
Budget End
1998-05-31
Support Year
14
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Geisinger Medical Center
Department
Type
DUNS #
City
Danville
State
PA
Country
United States
Zip Code
17822
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Patel, Krishna; Foster, Nathan R; Farrell, Ann et al. (2013) Oral cancer chemotherapy adherence and adherence assessment tools: a report from North Central Cancer Group Trial N0747 and a systematic review of the literature. J Cancer Educ 28:770-6
Barton, Debra L; Burger, Kelli; Novotny, Paul J et al. (2013) The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 21:1185-92

Showing the most recent 10 out of 115 publications